Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer

Maris Mezeckis; Vesprini Danny; Buryk Vladyslav; Miszczyk Leszek; Vjaters Egils

Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer

J Radiosurg SBRT. 2022;8(2):95-103.

Authors

Maris Mezeckis¹, Vesprini Danny², Buryk Vladyslav³, Miszczyk Leszek⁴, Vjaters Egils⁵

Affiliations

¹ University of Latvia, Sigulda Hospital Centre of Stereotactic Radiosurgery, Lakstigalas str. 13, Sigulda, LV-2150, Latvia, EU.
² University of Toronto, Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, T-wing 2075 Bayview Avenue TG 260, Toronto, ON, M4N 3M5, Canada.
³ Sigulda Hospital Centre of Stereotactic Radiosurgery, Lakstigalas str. 13, Sigulda, LV-2150, Latvia, EU.
⁴ Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice, Wybrzez˙e Armii Krajowej 15, 44-102 Gliwice, Poland, EU.
⁵ University of Latvia, P.Stradins Clinical University Hospital, Centre of Urology, Pilsonu str. 13, Riga, LV-1002, Latvia, EU.

PMID: 36275129
PMCID: PMC9489076

Abstract

Stereotactic body radiotherapy (SBRT) is well accepted for low- and intermediate-favorable risk prostate cancer. Available evidence about the application of SBRT in unfavorable- and high-risk prostate cancer is less solid. During last year's multiple variations in treatment, techniques have been reported making comparisons more complicated. This review's objective is to review current evidence in application of SBRT in intermediate unfavourable and high-risk prostate cancer and to outline variations in SBRT treatment techniques and relevant results.

Keywords: Intermediate unfavorable; SBRT; high-risk prostate cancer; stereotactic body radiotherapy.